These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27140928)

  • 1. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
    Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
    Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
    Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
    J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
    Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
    Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
    Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
    Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
    Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
    Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
    Andersen RJ; Mawji NR; Wang J; Wang G; Haile S; Myung JK; Watt K; Tam T; Yang YC; Bañuelos CA; Williams DE; McEwan IJ; Wang Y; Sadar MD
    Cancer Cell; 2010 Jun; 17(6):535-46. PubMed ID: 20541699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
    Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H
    Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.